David O'Malley, MD, highlights promising results from a subgroup analysis of the effect of platinum sensitivity on the efficacy of rucaparib vs chemo for BRCA–positive, advanced, relapsed ovarian carcinoma.
David O'Malley, MD, highlights promising results from a subgroup analysis of the effect of platinum sensitivity on the efficacy of rucaparib vs chemo for BRCA–positive, advanced, relapsed ovarian carcinoma.
David O'Malley, MD, highlights...